Background: Few prospective data have been published on the comparison of bone density and quality in homogeneous groups of patients with juvenile systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA). Objective and hypothesis: The objective of this study is to perform a longitudinal evaluation of the prevalence and the characteristics of bone mass and quality and to evaluate the differences on the bone parameters, using DXA, pQCT and QUS. Population and/or methods: Forty-three JSLE patients (35 females, 8 males, median age 18.8, range 14.0-34.1 years) have been studied with DXA, pQCT and QUS scans and compared with 138 JIA patients (112 females, 26 males, median age 18.9, range 13.4-33.2 years), and 79 controls (59 females, 20 males; median age 19.3, range 13.5-36.5 years). Of these, 39 patients (32 females and 7 males, median age 20.3, range 16.6-36.8 years) with JSLE were followed longitudinally and compared with 131 patients (108 females, 23 males median age 20.7, range 15.8-37.1 years) with JIA and 63 controls (48 females, 15 males; median age 21.9, range 15.5-38.3 years). Results: JSLE patients have a higher bone cortical density (CrtBMD) than controls and JIA patients (p < 0.005). However, JSLE and JIA patients have a significantly reduced bone trabecular density (TrbBMD) compared to controls (p < 0.0001), with no differences between JSLE and JIA. In addition, JIA patients show a significantly reduced muscle area (MuscleCSA) compared to JSLE and controls (p < 0.001). Conversely, fat area (FatCSA) is significantly increased both in JIA and JSLE patients when compared to controls (p < 0.001), with no differences between the JSLE and JIA groups. Analogous results are observed in the polar resistance to stress (SSIp).
Introduction
Numerous rheumatological disorders of childhood, such as juvenile dermatomyositis, juvenile idiopathic arthritis (JIA) and juvenile systemic lupus erythematosus (JSLE), are frequently characterized by significant reduction of bone mineral density (BMD) and quality. [1] [2] [3] [4] In these patients, multiple causes involving both disease-and non-disease-related factors, such as systemic inflammation, corticosteroid use, limited physical activity, reduced exposure to sunlight, puberty and growth delay, may contribute to reduced bone mass and quality. [5] [6] [7] [8] [9] [10] Unlike their adult counterparts, JSLE and JIA patients are at special risk of developing impaired bone mass and quality, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] with an increase of fracture risk in adulthood. [14] [15] [16] [17] Whereas many data seem to indicate heredity is one of the most important factors of variation in BMD, lifestyle or current diseases also have a central influence on peak bone mass (PBM). 12 In particular, the physiological interaction between muscle and bone represents an important factor in the outcome of JIA patients, 13, 18 whereas the data on JSLE patients are rarely reported. 12, 19 Imaging techniques commonly play a central role in the evaluation of bone status. 20 Of these, dual-energy X-ray absorptiometry (DXA) is the gold-standard tool in the measurement of densitometry, even if it precludes a direct measure of volumetric BMD (vBMD). Therefore, it is useful to use other methods better able to estimate a quantitative assessment of macrostructural and microstructural characteristics of the bone and to explain bone quality abnormalities. 20 Peripheral quantitative computed tomography (pQCT), a noninvasive, three-dimensional imaging technique able to measure real bone density in a determinate volume (mg/cm 3 ;), allow a selective assessment both of trabecular and cortical bone, thereby estimating bone strength. 12, 13, 20 However, pQCT has become a technique increasingly used to study the interaction between muscle and bone systems, 12, 13, 21, 22 showing significant bone microand macrostructural impairments in JIA and JSLE patients. 12, 13 Finally, quantitative ultrasonography (QUS), particularly indicated for its low cost, portability and lack of exposure to ionizing radiation, also permits the indirect evaluation of changes in trabecular and cortical architecture and accumulated fatigue. 23 Few data are reported in adults comparing SLE and rheumatoid arthritis (RA), 24 but limited studies are available comparing JIA and JSLE patients with respect to bone density and structure at the same time and in homogeneous groups. 25 In a study using a DXA instrument in 15 JSLE and five JIA children and adolescents, and comparing the results with 20 healthy controls, BMD in all patients was significantly lower than in controls, more prominently at lumbar vertebrae than at the femoral neck. 25 In another study, SLE patients had a higher frequency of osteoporosis compared with matched healthy controls, even if matched SLE and RA patients had similar BMD, prevalence of osteoporosis and reduced bone mass. 24 However, no data comparing JIA and JSLE using pQCT and QUS are reported in the literature.
The purpose of this study was to perform a longitudinal evaluation of the prevalence and the characteristics of bone mass and quality in JSLE patients and to evaluate the differences on the bone biomechanical parameters, using DXA, pQCT and QUS, in respect to two homogenous for age-and sex-matched groups of JIA patients and healthy controls.
Subjects and methods
A longitudinal study was performed involving patients recruited from the Department of Biomedicine, Section of Rheumatology, Transition Clinic of Florence University between May 2007 and February 2013. For the current study, lumbar DXA examination, forearm pQCT and phalangeal QUS scans were carried out contemporaneously. The study protocol was approved by our hospital ethics committee of Careggi Hospital and informed consent was obtained from all patients and/or parents.
Study population and design
We studied two homogeneous groups, 43 age-and sex-matched patients ( 26, 27 Some of the patients are reported in two different previous studies. 12, 13 Regarding the JIA patients, at study onset 89 had oligoarticular, 26 polyarticular, eight systemic, and 15 enthesitisarthritis (ERA) onset.
Thirty-nine patients (32 females and 7 males, median age 20.3 years, range 16.6-36.8 years) with JSLE and 131 patients (108 females, 23 males median age 20.7, range 15.8-37.1 years) with JIA, also were followed longitudinally with a second DXA, pQCT and QUS scan.
The cross-sectional and longitudinal data of JIA and JSLE patients were compared with two ageand sex-matched control groups of healthy subjects.
Study design
For each patient demographic and clinical data including disease onset, age at diagnosis, disease course, therapy, height, pubertal stage, weight and body mass index (BMI), use of glucocorticoids (duration, current and cumulative dose), and family history of osteoporosis were recorded.
Exclusion criteria for the study for patients and controls were the presence of bone metabolic diseases, genetic diseases and syndromes, hepatic diseases, hyper-/hypoparathyroidism, hyper/ hypothyroidism, chronic renal insufficiency, cancer, pregnancy, lactation, drug addiction, and previous or present anticonvulsant or bisphosphonate therapy.
Study and laboratory methods
Height and weight were measured as previously described. [11] [12] [13] BMI was calculated as weight divided by height squared (kg/m 2 ). Age-related reference values of height and BMI were obtained from a sample of Italian children. 28 Pubertal staging was carried out according to Tanner and Whitehouse's criteria (G ¼ Genitals in male stages (stage I -V); B ¼ Breasts in females stages (stage I -V). 29 Height and BMI were normalized for chronological age by conversion to standard deviation scores (SDS). 30 All subjects or their parents completed two questionnaires, determining calcium intake and physical activity levels. The first evaluated a detailed food frequency questionnaire and calcium calculator (www.osteoporosis.ca). The patient's calcium intake was classified as adequate or inadequate based on American Academy of Pediatrics recommendations. 31 The second questionnaire was a modified version of the Physical Activity Questionnaire for Children (PAQ-C), 32 which measures daily activity in the moderate to vigorous range over seven days' recall. General physical activity scores ranged from 1 (low activity) to 5 (high activity).
DXA examination
BMD (g/cm 2 ) was measured at the lumbar spine (L2-L4) using a strict protocol with the same instrument (Delphi-A System, Hologic Inc, Waltham, MA, USA). BMD was expressed as Z scores. Average BMD values for L2-L4 were used for calculations. For estimation of the volumetric density (bone mineral apparent density or BMAD), the formula of Kro¨ger et al. 33 was used:
Patients' BMAD was also expressed as Z scores to facilitate comparisons between JSLE and JIA patients and healthy controls.
All BMD measurements were performed by the same operator using a standardized protocol of measurement.
pQCT The left (nondominant) radius was measured by a single trained investigator, using a Norland-Stratec XCT 3000 scanner (Stratec Medical, Pforzheim, Germany).
The 2 mm-thick single tomographic slices, with a voxel size of 0.4 mm and the scan speed at 25 mm/s, were taken from the shaft and distal part of the radius (66% and 4% from the distal endplate of the radius, respectively). 12, 13, 20 Names for endpoint variables were chosen according to the Task Force on Standardization of Bone Structure and Density Assessment (http:// nomenclature.bb.asbmr.org/) for high-resolution pQCT
The 4% (distal) radial site allowed us to assess trabecular bone, obtaining total bone mineral density (TotBMD, mg/cm 3 ), and trabecular bone mineral density (TrbBMD, mg/cm 3 ). 12, 13, 20 For the shaft regions (66%), the analyzed bone traits were cortical bone mineral density (CrtBMD), total bone cross-sectional area (TotCSA, mm 2 ), cortical cross-sectional area (CorticalCSA), muscle cross-sectional area (MuscleCSA), fat crosssectional area (FatCSA, cm 2 ), and density-weighted polar section modulus (SSIp, mm 3 , an estimate of bending and torsional bone strength for cortical bone).
As growth retardation is common in JSLE and JIA children and adolescents, all bone size-dependent parameters (total, cortical, and MuscleCSA) were corrected for height.
QUS scans
Bone density was evaluated with a DBM Sonic 1200 device (IGEA Bone Profiler, Carpi, Italy), 24 evaluating with two probes mounted on an electronic caliper, phalanxes bone density. By this technique we have measured the amplitude-dependent speed of sound (AD-SoS, m/s; such as the interval between the start time of the transmitted signal and the time the signal received reaches the predetermined minimum amplitude value of 2 mV for the first time). 
Clinical assessment of disease activity
JLSE disease activity and damage were assessed by using the SLE Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), respectively. Laboratory assessments included titers of antidouble-stranded DNA (dsDNA), complement level (C3 and C4), C-reactive protein (CRP) and creatinine clearance. 12 In JIA patients the disease onset was defined as the date on which arthritis and/or systemic features were documented by a pediatric rheumatologist. 11, 13 The disease subtype and the active JIA assessment were defined according to the previous reported definition. 11, 13 Clinical assessment and laboratory evaluation were performed longitudinally to report the disease course and flares. 11, 13 Corticosteroids treatment
During the study, in order to define the task of these determinants on bone density and quality, patients were asked if they had received systemic corticosteroids, type, dose and duration of corticosteroid medication, and the estimated average cumulative daily dose of corticosteroids. For all systemic corticosteroids we have converted the steroid dosage to a common steroid equivalency.
Healthy control subjects
At the first DXA, the control group included 79 healthy age-and sex-matched subjects (59 females, 20 males; median age at DXA evaluation 19.3 years, range 13.5-36.5 years) seen for non-inflammatory musculoskeletal complaints. At the second evaluations, we selected a second control group with the same characteristics (63 subjects, 48 females, 15 males; median age 21.9 years, range 15.5-38.3 years). 11 All subjects were evaluated at the time of routine follow-ups, and parental informed consent was obtained.
Statistical analysis
Statistical analyses were performed by using SPSSX (SPSSX Inc, Chicago, IL, USA). Clinical variables considered relevant for the study were as follows: sex (male:female (M:F)), spine BMAD SDS, age at disease's onset, disease duration at the first and second evaluations, time from JSLE or JIA diagnosis to the first and second examinations (in years), disease activity at the first and second examinations, BMI SDS, height SDS, age of puberty onset, pubertal stage at the first and second examinations, erythrocyte sedimentation rate (ESR), CRP, hemoglobin, current and/or past corticosteroid use, type, dose and duration of corticosteroid medication.
Summaries of continuous variables are given as mean AE SD or median and range, depending on whether the data were normally distributed or not. Differences between patient groups and controls were assessed using the Student t test and Mann-Whitney U test, depending on the distribution of the analyzed variable. The chi-square test and Fisher's exact test were used as appropriate to examine associations between dichotomous variables. Inter-group comparisons for parameters were conducted using analysis of variance (ANOVA) or using repeated-measures analysis of covariance (ANCOVA), as appropriate. P values <0.05 were considered statistically significant.
Results
Main demographic, clinical and laboratory characteristics of JSLE and JIA patients and controls are summarized in Table 1 At the first DXA evaluation, the two groups of JSLE and JIA patients did not show difference regarding the spine BMAD SDS (À0.62 AE 1.13 vs. À0.60 AE 0.92, p ¼ NS), even if this parameter obviously was significantly reduced in comparison to controls (0.16 AE 0.49; p < 0.0001) (Figure 1(a) ). When compared with the different JIA subgroups, we showed that JSLE patients have a significantly different BMAD SDS only in respect to systemic (À1.44 AE 1.53; p < 0.0001), and ERA (0.12 AE 0.55; p < 0.001) onset. (Figure 2(a) ), without significant differences between JSLE and JIA groups. However, JSLE patients showed significantly different TrbBMD only in respect to systemic onset (149.6 AE 38.0, p < 0.005).
In contrast, JSLE patients had significant higher CortBMD (1106.5 AE 85.1 mg/cm 3 ) in comparison to healthy controls (1043.8 AE 95.6 mg/cm 3 , p < 0.005), and JIA patients (1032.2 AE 89.1 mg/cm 3 , p < 0.005) (Figure 3(a) ). Comparing to different JIA subgroups, JSLE patients showed a significantly different CortBMD in respect to oligoarticular (1050.7 AE 132.6 mg/cm 3 , p < 0.005), polyarticular (1060.0 AE 83.9 mg/cm 3 , p < 0.05) and systemic onset (999.7 AE 89.3 mg/cm 3 , p < 0.0001).
Yet, JSLE patients had normal CBA (197.0 AE 99.8 vs. 213.3 AE 56.9 mm 2 ) values with respect to controls, whereas they showed significantly higher values than JIA patients (139.8 AE 103.1, p < 0.0001) (Figure 4(a) ). These results were confirmed when JSLE patients were compared with oligoarticular (144.0 AE 95.0 mm 2 , p < 0.005), and systemic onset (129.3 AE 54.6 mm 2 , p < 0.0001).
Remarkably, JSLE patients showed muscle CSA values not significantly reduced with respect to controls (2440.9 AE 589.5 vs. 2300.6 AE 675.8 mm 2 , p ¼ NS), whereas it was significantly higher than in JIA patients (2126.9 AE 712.3, p < 0.0005) ( Figure 5(a) ). These results were also confirmed comparing JSLE patients with oligoarticular (2152 AE 843.2, p < 0.05), polyarticular (2109.9 AE 783.1 mm 2 , p < 0.001), and systemic (2045.8 AE 612.0 mm 2 , p < 0.0001) onset.
However, FatCSA was significantly increased in JSLE (1222.3 AE 524.6 mm 2 ) and JIA (1161.8 AE 634.7 mm 2 ) patients with respect to healthy controls (822.0 AE 299.9 mm 2 , p < 0.0001) ( Figure 6(a) ), without significant differences between the two diseases. Evaluating FatCSA in JSLE patients and JIA subgroups, we observed a significantly statistical difference among JSLE patients and oligoarticular (1108.1 AE 434.9 mm 2 , p < 0.005), polyarticular (1077.0 AE 483.7 mm 2 , p < 0.0005), but not with systemic (1265.3 AE 339.8 mm 2 ), and ERA onset (1289.7 AE 766.8 mm 2 ).
However, SSIp levels were significantly lower in JSLE and JIA patients than in controls (242.1 AE 90.7 mm 3 and 239.8 AE 97.6 mm 3 vs. 298.6 AE 106.0 mm 3 , p < 0.05) (Figure 7(a) ), without statistical differences between the two diseases.
Finally, AD-SoS was confirmed to be significantly reduced in patients with JSLE and JIA (2050.9 AE 103.4 and 1999.6 AE 113.4 m/s) than (Figure 8(a) ). Analyzing JIA subgroups and JSLE patients, we disclosed significant differences only between JSLE patients and JIA systemic onset patients (1899.3 AE 121.5 m/s, p < 0.0001).
Longitudinal evaluation
Main demographic, clinical and laboratory characteristics of longitudinal evaluation of JSLE patients with respect to JIA patients and controls are summarized in Table 1 . The longitudinal evaluation confirmed that JSLE patients maintain a reduced spine BMAD SDS (À0.70 AE 1.17) compared to controls (0.14 AE 0.90; p < 0.0001), but not in comparison to JIA patients (À0.54 AE 1.05), without significant statistical differences with respect to cross-sectional evaluation (Figure 1(b) ). However, when related to different JIA subgroups, we detected significant differences among JLSE patients vs. systemic and ERA onsets (p < 0.001). However, TrbBMD levels were confirmed to be significantly lower in JSLE patients than controls (160.2 AE 46.9 vs. 229.7 AE 46.3 mg/cm 3 , p < 0.005), and JIA patients (183.9 AE 53.8 mg/cm 3 , p < 0.05) (Figure 2(b) ). Nevertheless, we did not observe differences between TrbBMD levels in JSLE and JIA patients in respect to cross-sectional evaluation, with the exception being with respect to systemic onset (155.0 AE 28.5, p < 0.005).
Still, CortBMD values in JSLE were not significantly different in respect to controls (1078.9 AE 120.6 vs. 1046.6 AE 79.1, p ¼ NS) and JIA patients (1045.7 AE 96.8, p ¼ NS) (Figure 3(b) ). CBA values were significantly reduced in JSLE patients (155.0 AE 29.3 mm 2 ) in comparison to controls (219.8 AE 79.9 mm 2 , p < 0.005), but not in JIA patients (149.0 AE 87.6 mm 2 , p ¼ NS) (Figure 4(b) ). Nevertheless, we detected a significant difference The longitudinal assessment of muscle CSA showed that this parameter was not significantly reduced in JSLE patients with respect to controls (2452.2 AE 334.4 vs. 2567.9 AE778.4 mm 2 , p ¼ NS), according to the first evaluation, but differently with respect to JIA patients, in which MuscleCSA was still significantly reduced (2094.7 AE 678.9 mm 2 , p < 0.005) ( Figure 5(b) ).
FatCSA values remained significantly increased in JSLE patients over controls (1289.8 AE 445.3 vs. 959.5 AE 374.2 mm 2 , p < 0.0005), though not significantly different from the first evaluation (1178.8 AE 489.7, p ¼ NS), and significantly higher with respect to JIA patients (p < 0.0005) ( Figure 6(b) ). (Figure 8(b) ).
Discussion
Our results confirm that the impaired bone mass and quality of adolescents and young adults with JSLE do no significantly ameliorate over time compared to healthy subjects, but similarly to JIA patients, show lower values of BMAD, TrbBMD, and AD-SoS than controls.
In addition, our study remarkably demonstrated a persistent impaired bone accrual over years, even if in JSLE, in contrast to JIA patients, it is not associated with a significant musculoskeletal deficit, delineating a different role of muscle mass in JSLE patients in conditioning the impaired bone mass in the two diseases. This could be related to reduced physical activity, generally more evident in JIA than in patients with JSLE. 31 Therefore, on the basis of previous 12 and current data and the study of Trapani et al. 8 and Lilleby et al., 34 we confirm that the PBM may be lower in JSLE than in healthy adolescents or adults, with a lack of BMD catch-up when patients are entering adulthood. Moreover, our data also provide evidence that many parameters of bone structure are involved in JSLE patients, whereas other parameters can normalize with time, probably reflecting the amelioration of inflammatory status by treatments.
So, the reduced values of BMAD and other bone structure parameters evaluated by pQCT and QUS support the potential risk of chronic diseases deteriorating normal bone accrual and health. Moreover, as shown previously, 12 a very interesting datum in this study is the high value of FatCSA in JSLE with respect to JIA, in both significantly higher than in healthy controls. The link between fat area and reduced BMD remains unclear. As reported, 35 we may hypothesize that chronic systemic inflammation in JSLE may increase lipogenesis in nonadipose tissues and lipolysis in white adipose tissue, resulting in ectopic lipid deposition in nonadipose tissues, like muscle and liver. The production of proinflammatory cytokines characterizing an autoimmune disorder like SLE could be associated, on the one side, with an increased secretion of leptin and ectopic lipid accumulation in skeletal muscles, or on the other side with a higher bone turnover and consequent loss of bone mass. So, while DXA and QUS appear, as the pQCT technique, able to highlight the differences between healthy controls and patients with JSLE and JIA regarding bone density and quality, our data seem to demonstrate that only pQCT may represent a technique capable of highlighting the differences between these two diseases. This could suggest the use of this important method in assessing the longitudinal course of JSLE patients and may suggest a different pathogenesis of bone damage in these patients, hypothesizing future different treatments for these two diseases.
In conclusion, patients with JSLE have a low bone mass without catch-up growth over time, leading to a reduced final peak bone mass with a high risk of osteoporosis in early adulthood. To reduce the risk, a close monitoring of BMD, a better control of disease activity, physical activity, and a dietary intake of calcium and vitamin D may be advocated to ameliorate bone mass. In patients with proved osteoporosis, therapeutic approaches including bisphosphonates should be considered. 
